News

AbbVie begins Phase 3 diabetic nephropathy study of atrasentan
Wednesday, May 22, 2013 Research-based biopharmaceutical company AbbVie has started Phase 3 in study of investigational compound atrasentan on renal outcomes in patients with diabetic...

Pfizer ends inotuzumab ozogamicin Phase 3 non-Hodgkin lymphoma study
Tuesday, May 21, 2013 Pfizer has stopped the Phase 3 randomised, open-label study (B1931008) of inotuzumab ozogamicin in relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma...

R-Tech begins patient enrolment in Phase I/II severe dry eye study
Tuesday, May 21, 2013 R-Tech Ueno has started patient enrolment in Phase I/II study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in the US for treating severe dry...

Novo Nordisk announces positive results from phase 3 haemophilia B trial
Monday, May 20, 2013 Novo Nordisk has announced positive results from phase 3 trial with long-acting factor IX, glycopegylated recombinant factor IX (N9-GP), for treatment of haemophilia...

NW Bio commences Phase III trial of DCVax-L for brain cancer
Monday, May 20, 2013 Northwest Biotherapeutics (NW Bio) has announced the commencement of a Phase III trial with DCVax-L for brain cancer at King's College Hospital in the...

Trillium completes dosing in Phase I cystitis/bladder pain syndrome study of TTI-1612
Friday, May 17, 2013 Trillium Therapeutics, a wholly-owned subsidiary of Stem Cell Therapeutics has completed dosing in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) in the Phase I study of...

FDA approves Xofigo prostate cancer drug
Friday, May 17, 2013 The USFDA has approved Xofigo (radium Ra 223 dichloride) for the treatment of advanced prostate cancer three months ahead of schedule under the priority review...

Sanofi, Regeneron announce patient enrolment in sarilumab Phase III trials
Thursday, May 16, 2013 Sanofi and Regeneron Pharmaceuticals have announced patient enrolment in two Phase III trials, Compare and Ascertain, to assess sarilumab as a treatment for rheumatoid arthritis...

Soligenix commences Phase I paediatric Crohn's disease study of SGX203
Thursday, May 16, 2013 Clinical-stage biopharmaceutical company Soligenix has initiated a Phase I study of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) to treat paediatric Crohn's...

OncoMed initiates Phase Ib/II small cell lung cancer trial of OMP-59R5
Wednesday, May 15, 2013 OncoMed Pharmaceuticals has initiated a Phase Ib/II trial of anti-cancer stem cell therapeutic OMP-59R5 (Anti-Notch2/3) in small cell lung cancer...

Mirna initiates Phase I trial of anti-cancer drug MRX34
Wednesday, May 15, 2013 MicroRNA therapy developer Mirna Therapeutics has commenced a Phase I trial of anti-cancer drug...

MorphoSys commences patient dosing in Phase II study of lymphoma drug
Tuesday, May 14, 2013 MorphoSys has commenced patient dosing in a Phase II study of anti-CD19 antibody MOR208 for the treatment of non-Hodgkin's lymphoma...

Relypsa completes enrolment in patiromer Phase III programme to treat hyperkalemia
Tuesday, May 14, 2013 Clinical-stage biopharmaceutical company Relypsa has finished enrolling patients with chronic kidney disease (CKD) in a pivotal Phase III programme of patiromer for the treatment of...

Eli Lilly reports poor results from Phase III diffuse large B-cell lymphoma study
Monday, May 13, 2013 Eli Lilly and Company has announced that a Phase III study designed to evaluate enzastaurin as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL)...

Prometheus commences enrolment in Phase IV trial of Proleukin
Monday, May 13, 2013 Specialty pharmaceutical and diagnostic company Prometheus Laboratories has commenced enrolment in a multicentre Phase IV trial evaluating Proleukin (high-dose interleukin-2 (HD IL-2)), along...

Onconova completes enrolment in Phase III study of rigosertib
Friday, May 10, 2013 Clinical-stage biopharmaceutical company Onconova Therapeutics has completed enrolment in its ONTIME pivotal Phase III study of rigosertib in patients with high-risk myelodysplastic...

Trevena, Forest Laboratories partner to develop cardiovascular drug
Friday, May 10, 2013 Trevena and Forest Laboratories have collaborated to develop TRV027, an AT1R biased-ligand for the treatment of acute heart...

Celsus reports interim results from first cohort of Phase II ACD trial
Thursday, May 09, 2013 Celsus Therapeutics has reported positive interim results from the first cohort of its Phase II trial of MRX-6 for the treatment of patients with allergic contact dermatitis...

Regenerys takes over Altrika from Ilika
Thursday, May 09, 2013 UK-based regenerative medicine company Regenerys has announced the acquisition of Altrika from its parent company...

Ablynx commences pre-clinical development of allergic asthma anti-IgE nanobody
Wednesday, May 08, 2013 Ablynx has commenced pre-clinical development of ALX-0962, an anti-immunoglobulin E (IgE) nanobody, to treat severe allergic...